Identification of compounds for inhibiting complexation of C-reactive protein with fibronectin

• US 7,645,583 B2
• Filed: 12/14/2005
• Issued: 01/12/2010
• Est. Priority Date: 12/14/2005
• Status: Expired due to Fees

• Current Assignee: Kimberly-Clark Worldwide Incorporated (Kimberly-Clark Corporation)
• Original Assignee: Kimberly-Clark Worldwide Incorporated (Kimberly-Clark Corporation)
• Inventors: Malik, Sohail, Quirk, Stephen, Boga, RameshBabu
• Primary Examiner(s): Haq; Shafiqul
• Application Number:
  US11/302,994
• Publication Number:
  US 20070134813A1
• Time in Patent Office: 1,490 Days
• Field of Search: None
• US Class Current: 435/7.1
• CPC Class Codes: G01N 2333/4737 C-reactive protein
• CPC Class Codes: G01N 2333/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: G01N 2500/02 Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
• CPC Class Codes: G01N 33/54388 based on lateral flow
• CPC Class Codes: G01N 33/558 using diffusion or migration of antigen or antibody immunochromatographic test strips G01N33/54387
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92
• CPC Class Codes: Y10S 436/815 Test for named compound or class of compounds

Abstract

Disclosed are screening processes for identification of compounds that may inhibit complex formation between C-reactive protein and fibronectin. Compounds identified by the disclosed methods may be utilized to inhibit the target analytes that are known to occur during skin aging as well as during the course of several diseases. Accordingly, inhibitory compounds identified by the disclosed methods may be utilized to prevent and treat damaged tissue, inflammatory conditions, cardiovascular conditions, renal conditions, periodontal conditions and obesity, among other conditions. For example, the compounds identified by the disclosed methods may be utilized to treat tissue that has suffered trauma, e.g., burns or wounds, as well as tissue that is inflamed due to any of several causes. The disclosed compounds may also be utilized to improve the accuracy of assays designed to assess CRP or Fn levels in a sample, for instance in a plasma sample, as a risk assessment tool in certain medical conditions and to discover new treatments.

Claims

1. A method for identifying a gibberellic acid or a jasmonic acid compound that inhibits the complexation of C-reactive protein with fibronectin, the method comprising:

contacting a first polypeptide with a second polypeptide in the presence of a gibberellic acid or jasmonic acid test compound to form a complex of the first polypeptide with the second polypeptide, the first polypeptide comprising at least a segment of a C-reactive protein, the first polypeptide including the fibronectin binding site of the C-reactive protein and the second polypeptide comprising at least a segment of a fibronectin protein, the second polypeptide including the C-reactive binding site of the fibronectin; and

determining whether complexation of the first polypeptide with the second polypeptide is decreased in the presence of said gibberellic acid or jasmonic acid test compound as compared to a control containing no gibberellic acid or jasmonic acid compound, wherein the first polypeptide and the second polypeptide form a complex in the absence of gibberellic acid or jasmonic acid compound and a decrease in said complexation is an indication that said gibberellic acid or jasmonic acid compound inhibits the complexation of C-reactive protein to fibronectin.

2. The method of claim 1, wherein either the first polypeptide or the second polypeptide is immobilized in a detection zone of a separation device.

3. The method of claim 2, wherein the step of determining whether complexation of the first polypeptide with the second polypeptide is decreased in the presence of the gibberellic acid or jasmonic acid compound includes generating a detection signal within the detection zone, the detection signal corresponding to the complexation of the first polypeptide with the second polypeptide.

4. The method of claim 2, wherein the detection zone is in fluid communication with detection probes for generating the detection signal.

5. The method of claim 4, wherein the detection probes are conjugated with the first polypeptide.

6. The method of claim 4, wherein the detection probes are conjugated with the second polypeptide.

7. The method of claim 1, wherein the first polypeptide comprises SEQ ID NO.:

20.

8. The method of claim 1, wherein the first polypeptide comprises SEQ ID NO.:

19.

9. The method of claim 1, wherein the second polypeptide comprises SEQ ID NO.:

18.

10. The method of claim 1, wherein the second polypeptide comprises SEQ ID NO.:

17.

11. The method of claim 2, the separation device comprising a fluidic medium, the method further comprising applying a test sample including the gibberellic acid or jasmonic acid compound to the fluidic medium at an application site, the gibberellic acid or a jasmonic acid compound flowing through the fluidic medium from the application site to the detection zone within which the first polypeptide contacts the second polypeptide in the presence of the gibberellic acid or jasmonic acid test compound.

12. The method of claim 11, the separation device further comprising a conjugate pad located upstream of the detection zone, the conjugate pad carrying detection probes in dehydrated form that are free to migrate upon rehydration with the test sample.

13. The method of claim 12, wherein the detection probes are modified with either the first polypeptide or the second polypeptide to form conjugated detection probes.

14. The method of claim 11, the separation device further comprising an absorbent pad located downstream from the detection zone, the method further comprising the test sample flowing from the application zone to the detection zone and then to the absorbent pad.

15. The method of claim 11, the method further comprising combining the test sample with either the first polypeptide or the second polypeptide upstream of the detection zone.

16. The method of claim 15, wherein the first polypeptide or the second polypeptide that is combined with the test sample upstream of the detection zone is modified with detection probes to form conjugated detection probes.

17. The method of claim 15, wherein the first polypeptide or the second polypeptide that is combined with the test sample upstream of the detection zone is combined with the test sample prior to application of the test sample to the fluidic medium.